Association of thyroid function test abnormalities and thyroid autoimmunity with preterm birth: a systematic review and meta-analysis by Korevaar, Tim I. M. et al.
Association of Thyroid Function Test Abnormalities
and Thyroid AutoimmunityWith Preterm Birth
A Systematic Review andMeta-analysis
The Consortium on Thyroid and Pregnancy—Study Group on Preterm Birth
IMPORTANCE Maternal hypothyroidism and hyperthyroidism are risk factors for preterm
birth. Milder thyroid function test abnormalities and thyroid autoimmunity are more
prevalent, but it remains controversial if these are associated with preterm birth.
OBJECTIVE To study if maternal thyroid function test abnormalities and thyroid
autoimmunity are risk factors for preterm birth.
DATA SOURCES AND STUDY SELECTION Studies were identified through a search of the
Ovid MEDLINE, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials,
and Google Scholar databases from inception to March 18, 2018, and by publishing open
invitations in relevant journals. Data sets from published and unpublished prospective
cohort studies with data on thyroid function tests (thyrotropin [often referred to as
thyroid-stimulating hormone or TSH] and free thyroxine [FT4] concentrations) or thyroid
peroxidase (TPO) antibodymeasurements and gestational age at birth were screened for
eligibility by 2 independent reviewers. Studies in which participants received treatment
based on abnormal thyroid function tests were excluded.
DATA EXTRACTION AND SYNTHESIS The primary authors provided individual participant
data that were analyzed using mixed-effects models.
MAIN OUTCOMES ANDMEASURES The primary outcomewas preterm birth
(<37 weeks’ gestational age).
RESULTS From 2526 published reports, 35 cohorts were invited to participate. After the
addition of 5 unpublished data sets, a total of 19 cohorts were included. The study population
included 47045 pregnant women (mean age, 29 years; median gestational age at blood
sampling, 12.9 weeks), of whom 1234 (3.1%) had subclinical hypothyroidism (increased
thyrotropin concentration with normal FT4 concentration), 904 (2.2%) had isolated
hypothyroxinemia (decreased FT4 concentration with normal thyrotropin concentration),
and 3043 (7.5%) were TPO antibody positive; 2357 (5.0%) had a preterm birth. The risk of
preterm birth was higher for womenwith subclinical hypothyroidism than euthyroid women
(6.1% vs 5.0%, respectively; absolute risk difference, 1.4% [95% CI, 0%-3.2%]; odds ratio
[OR], 1.29 [95% CI, 1.01-1.64]). Among womenwith isolated hypothyroxinemia, the risk of
preterm birth was 7.1% vs 5.0% in euthyroid women (absolute risk difference, 2.3% [95% CI,
0.6%-4.5%]; OR, 1.46 [95% CI, 1.12-1.90]). In continuous analyses, each 1-SD higher maternal
thyrotropin concentration was associated with a higher risk of preterm birth (absolute risk
difference, 0.2% [95% CI, 0%-0.4%] per 1 SD; OR, 1.04 [95% CI, 1.00-1.09] per 1 SD).
Thyroid peroxidase antibody–positive women had a higher risk of preterm birth
vs TPO antibody–negative women (6.6% vs 4.9%, respectively; absolute risk difference,
1.6% [95% CI, 0.7%-2.8%]; OR, 1.33 [95% CI, 1.15-1.56]).
CONCLUSIONS AND RELEVANCE Among pregnant womenwithout overt thyroid disease,
subclinical hypothyroidism, isolated hypothyroxinemia, and TPO antibody positivity were
significantly associated with higher risk of preterm birth. These results provide insights
toward optimizing clinical decision-making strategies that should consider the potential
harms and benefits of screening programs and levothyroxine treatment during pregnancy.
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P reterm birth complicates 5% to 15% of births world-wide. It is the most important direct cause of morbid-ity andmortality in childrenyounger than5years,1 and
is an important risk factor for psychiatric, metabolic, cardio-
vascular, and renal disease later in life.2,3 However, in thema-
jority of cases, no known risk factors can be identified.4,5
Thyroid hormone regulates metabolism, growth, and
development in most tissues of the human body, including
various physiological processes related to preterm birth,
such as placental development and function, fetal growth,
and expression of neuropeptides involved in the onset of
labor.6-9 Overt hypothyroidism and hyperthyroidism during
pregnancy are well-known risk factors for preterm birth and
occur in approximately 0.5% and 0.05% of pregnancies,
respectively.10,11 During pregnancy, thyroid function test
abnormalities (subclinical hypothyroidism and isolated
hypothyroxinemia) and thyroid autoimmunity are much
more frequent than overt thyroid disease.11 However, it
remains to be determined whether such thyroid function
test abnormalities are risk factors for preterm birth.
Estimates for the association of subclinical hypothy-
roidism or isolated hypothyroxinemia with preterm birth in
previous observational studies range from odds ratios (ORs)
of 0.57 to 3.3.12-15 The interpretation of these studies is
limited by 2 main factors. First, the studies have used dif-
ferent upper limits for thyrotropin (often referred to as
thyroid-stimulating hormone or TSH; ranging from >2.5 to
>6.0 mIU/L). Second, most are single-center studies and
lack statistical power. Furthermore, only a few studies have
investigated whether isolated hypothyroxinemia could be a
risk factor for adverse pregnancy outcomes.
This study assessedwhether thyroid function test abnor-
malities and thyroidperoxidase (TPO)antibodypositivitywere
associated with preterm birth.
Methods
The Consortium on Thyroid and Pregnancy is a collaboration
of prospective birth cohorts that aims to study the associa-
tion of maternal thyroid function and autoimmunity with
adversepregnancy and child outcomes. For the current study,
we followed Preferred Reporting Items for Systematic Re-
views and Meta-Analyses guidelines for Individual Patient
Dataandpreregistered thestudyprotocol (CRD42016043494),
which appears in Supplement 1 along with an outline of
protocol deviations.
To identify studies for inclusion, we conducted a sys-
tematic literature search for articles on the association of
thyroid function or autoimmunity with preterm birth pub-
lished from database inception to March 18, 2018, without
language restrictions, using the Ovid MEDLINE, EMBASE,
Web of Science, Cochrane Central Register of Controlled
Trials, and Google Scholar databases (eMethods in Supple-
ment 2). In addition, unpublished data were identified via
open invitations sent to relevant journals,16,17 international
conferences, social media, and personal contacts. The
search was repeated on June 19, 2019, to identify studies
published after March 18, 2018, that would have been eli-
gible for inclusion.
We includedprospective cohort studies that includedpar-
ticipants consecutively without selection criteria related to
healthstatus (suchascomorbiditiesor thyroiddisease)andhad
data on thyrotropin concentration, free thyroxine (FT4) con-
centration, or TPO antibody measurements and data on ges-
tational age at birth. We excluded studies in which partici-
pants received treatment basedonabnormal thyroid function
tests (predominantly hospital-based cohorts) or studies that
only included women with overt thyroid disease.
Possible studies for inclusion were independently as-
sessed for suitability by 2 of the authors (T.I.M.K. and P.N.T.)
and anydisagreementwas resolvedbydiscussionwith a third
author (R.P.P.). Investigators fromeacheligible studywere in-
vited to join theconsortium.Studyqualityandriskofbiaswere
assessed using the Newcastle-Ottawa scale.
Local institutional review board approval and participant
informed consent was obtained for all separate cohorts;
no additional approvals were obtained for the current
study. After obtaining individual participant data, all partici-
pants with data on thyrotropin concentration, FT4 concentra-
tion, or TPO antibody concentration, and gestational age at
birth were included. We excluded participants who had a
miscarriage or perinatal death, preexisting thyroid disease,
thyroid-interfering medication use, in vitro fertilization, or
multiple pregnancies.
Primary and Secondary Outcomes
The primary outcome was preterm birth defined as a gesta-
tional age at birth of less than 37 weeks. Gestational age was
assessed using either ultrasoundmeasurements or time after
the lastmenstrual period. Secondaryoutcomeswereverypre-
termbirth (<32weeks’ gestational age) and thegestational age
at birth.
Exposures
Exposure variables included thyroid function test abnormali-
ties, continuous thyroid function test measurements (thyro-
tropin and FT4 concentrations), TPO antibody positivity,
and thyroglobulin antibody positivity. Thyroid function
test abnormalities were defined according to cohort-specific
Key Points
Question Are thyroid function test abnormalities or thyroid
autoimmunity a risk factor for preterm birth?
Findings In this individual participant data meta-analysis of
19 prospective cohort studies including 47045 women,
subclinical hypothyroidism (odds ratio [OR], 1.29), isolated
hypothyroxinemia (OR, 1.46), and thyroid peroxidase antibody
positivity (OR, 1.33) were each significantly associated with
a higher risk of preterm birth.
Meaning These findings provide evidence that subclinical
hypothyroidism, isolated hypothyroxinemia, and thyroid
peroxidase antibody positivity in pregnant women are risk factors
for preterm birth.
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2.5th and 97.5th population percentiles for thyrotropin and
FT4 concentrations after exclusion of TPO antibody–positive
women. Subclinical hypothyroidism was defined as a thyro-
tropin concentration above the 97.5th percentile and a FT4
concentration within the normal range (ie, 2.5th-97.5th per-
centile). Overt hyperthyroidism was defined as a thyrotropin
concentration below the 2.5th percentile and a FT4 concen-
tration above the 97.5th percentile. Subclinical hyperthyroid-
ism was defined as a thyrotropin concentration below the
2.5th percentile and a FT4 concentration within the normal
range. Isolated hypothyroxinemia was defined as a FT4
concentration below the 2.5th percentile and a thyrotropin
concentration within the normal range. Thyroid peroxidase
antibody positivity and thyroglobulin antibody positivity
were defined in a cohort-specific manner according to cut-
offs recommended by the manufacturer. For analyses with
continuous thyrotropin and FT4 concentrations as exposure
variables, the concentrations for all cohorts were log-
transformed and then standardized to population-specific
standard deviation scores after removal of outliers (±4 SD
from the mean) to enable comparisons among different
cohorts and assays.
Statistical Analyses
Primary Analyses
Westudied the associationof thyroid function test abnormali-
ties (the referencegroupwaswomenwithnormal thyroid), thy-
rotropin and FT4 concentrations continuously, and TPO and
thyroglobulin antibodypositivitywithpretermbirth andvery
pretermbirthusinggeneralized linearmixedmodelswitharan-
dom intercept for each cohort. For the sameexposures, the as-
sociation with gestational age at birth was studied using lin-
ear mixed models with a random intercept for each cohort.
The primary analyses were repeated with a 2-step ap-
proach by using random-effect models according to the Der-
SimonianandLairdmethodtopoolestimatesandtheFirthbias
reduction method in case of near or complete separation in
smaller cohorts. Heterogeneity across studies was assessed
usingthe I2statistic.Toevaluatepotentialpublicationbias, fun-
nel plots and Egger tests were used. All analyses were ad-
justed for maternal age, body mass index (BMI), ethnicity,
smoking, parity, gestational age at blood sampling, and fetal
sex.Weusedmultilevelmultiple imputation18 formissingdata
oncovariates. Five imputeddata setswere createdandpooled
for analyses using Rubin rules.19
Secondary and Sensitivity Analyses
We performed a prespecified sensitivity analysis for which
analyses on thyroid function or thyroid function test abnor-
malities were additionally adjusted for TPO antibody positiv-
ity. A post hoc sensitivity analysis assessed whether the asso-
ciation of TPO antibody positivity with preterm birth and
very preterm birth differed for each increase in continuous
thyrotropin concentration by adding a product interaction
term into the models and stratification of analyses according
to thyrotropin cutoffs recommended by the guidelines of the
American Thyroid Association.20 To assess TPO antibody
positivity, a post hoc sensitivity analysis explored different
cutoffs based on a recent study showing a dose-dependent
effect on thyroid function (alternative cutoffs: 94th popula-
tion percentile, higher absolute concentrations of >100
and >500 mIU/L, and higher relative concentrations of 2 ×
and 5 × the assay cutoff).21 In addition, a prespecified analy-
sis explored whether the association of thyrotropin concen-
tration, FT4 concentration, or TPO antibody positivity dif-
fered according to differences in gestational age at the time of
blood sampling, BMI, or parity.
A 2-sided threshold for statistical significance of <.05was
used. Because no adjustment was made for multiple testing,
findings from the secondary analyses and sensitivity analy-
ses should be interpreted as exploratory. All statistical analy-
ses were performed using R version 3.4.4 (R Project for Sta-
tistical Computing).
Results
From2526 published reports, 133 remained eligible for inclu-
sion based on screening of the title and abstract (Figure 1). Af-
ter reading the full text, a total of 35 cohorts were invited to
participate. Five unpublished data sets were added via per-
sonal contacts andresponses fromopen invitations.Four stud-
ieswerepublishedafter the indexdateofour systematic search
that otherwise would have been eligible for inclusion. A total
of 19 cohorts fromEurope, theUnited States, Chile, Australia,
Pakistan, and Japan responded to the invitation andwere able
to participate.
After exclusions, the final study population comprised
47045 participants (Figure 1), of whom 1234 (3.1%) had sub-
clinical hypothyroidism (increased thyrotropin concentra-
tionwith normal FT4 concentration), 904 (2.2%) had isolated
hypothyroxinemia (decreased FT4 concentration with nor-
mal thyrotropin concentration), and3043 (7.5%)wereTPOan-
tibody positive. Preterm birth and very preterm birth oc-
curred in2357 (5.0%)and349 (0.7%)pregnancies, respectively
(Table). Cohort-specific population characteristics, details on
data collection, cohort-specific number of participants with
available thyroid function and gestational age at birth, data
quality assessment by the Newcastle-Ottawa scale (indicat-
ing high-quality data for all cohorts), and cohort-specific per-
centile cutoffs for thyroid function test abnormalities (thyro-
tropin and FT4 concentrations) appear in eTables 1-4 in
Supplement 2.
Data on specific covariates were missing for up to 33% of
the women and from as many as 3 cohorts (total percentage
of missing data for maternal age: 0.3% [0 cohorts]; gesta-
tional age at the timeofblood sampling:0.4%[0cohorts]; par-
ity: 5.8% [1 cohort]; smoking status: 7.2% [1 cohort]; sex of the
child: 21.4% [2 cohorts]; BMI: 32.9% [3 cohorts]). Thewomen
thatwere not included due tomissing data on gestational age
at birth had similar mean standardized thyrotropin concen-
trations in SDs vs those who were included (−0.03 vs 0, re-
spectively;P = .28), but differentmean standardizedFT4 con-
centrations inSDs (0.06vs0;P = .05)anddifferentproportions
withTPOantibodypositivity (13.0%vs7.5%;P < .001) (eTable5
in Supplement 2).
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Preterm and Very Preterm Birth
Thyroid Function Test Abnormalities
Womenwith subclinical hypothyroidism had a higher risk of
preterm birth vs euthyroid women (6.1% vs 5.0%, respec-
tively; absolute riskdifference, 1.4%[95%CI,0%to3.2%];OR,
1.29 [95%CI, 1.01 to 1.64]), but not of verypretermbirth (0.7%
vs0.8%;absolute riskdifference,0%[95%CI, −0.3%to0.8%];
OR, 1.03 [95% CI, 0.52 to 1.20]; Figure 2). Women with iso-
lated hypothyroxinemia had a higher risk of preterm birth vs
euthyroidwomen(7.1%vs5.0%, respectively; absolute riskdif-
ference, 2.3% [95% CI, 0.6% to 4.5%]; OR, 1.46 [95% CI, 1.12
to 1.90]) and ahigher risk of very pretermbirth (1.9%vs0.8%;
absolute riskdifference, 1.2% [95%CI,0.4%to2.5%];OR, 2.57
[95% CI, 1.55 to 4.27]). Among women with overt hyperthy-
roidism, therewasno statistically significant difference in the
rate of preterm birth vs euthyroid women (4.0% vs 5.0%, re-
spectively; absolute risk difference, −1.2% [95% CI, −2.8% to
1.7%]; OR, 0.76 [95% CI, 0.43 to 1.34]; Figure 2).
Continuous Analyses of Thyroid Function
Continuous analyses showed that each 1-SD higher maternal
thyrotropin concentrationwas significantly associatedwith a
4% higher relative risk of preterm birth (absolute risk differ-
ence, 0.2% [95% CI, 0% to 0.4%] per 1 SD; OR, 1.04 [95% CI,
1.00 to 1.09]per 1 SD), butnotverypretermbirth (absolute risk
difference, 0% [95% CI, −0.05% to 0.10%] per 1 SD; OR, 1.04
[95%CI, 0.93 to 1.16] per 1 SD;Figure 3 andeTable 6 in Supple-
ment 2). Each 1-SDhighermaternal FT4 concentrationwasnot
associated with preterm birth, but was significantly associ-
atedwith a 12% lower risk of very pretermbirth (absolute risk
Figure 1. Flowchart of the Study and Participant Selections
2526 Studies identified from systematic
database search
2393 Studies excluded based on review
of title or abstract
52 Studies excluded
16 No original research
13 No exposure or outcome measurement
13 Selected population
7 Intervention or treatment
3 Not prospective or cohort study
8380 Women excluded
6220 Data unavailable for exposure
or outcome
945 Preexisting thyroid disease
603 Twin pregnancy
331 Miscarriage
281 In vitro fertilization
133 Potentially relevant studies
identified for further review
21 Cohorts excluded
11 Investigators not reachable
10 Declined participation (primary
investigator retired or data sharing issue)
19 Data sets included
55 425 Pregnant women
14 Identified by database search
5 Identified via personal contacts
and open invitations
81 Eligible studies based on full review
35 Data sets of cohorts
47 045 Women with data availability
46 421 Thyrotropin
46 291 Free thyroxine
40 559 Thyroid peroxidase antibody
              18 548 Thyroglobulin antibody
Table. Characteristics of the Total Study Population (N = 47045)
No. of Participants/
Total No. (%)a
Median
(95% Range)
Maternal Demographics
Age, y 46 893 29.0 (5.2)b
Gestational age
at blood sampling, wk
46 876 12.9 (7.0-39.7)
Body mass indexc 31 728 23.9 (4.4)b
Parity
0 24 180/44 336 (54.5)
1 13 217/44 336 (29.8)
2 4435/44 336 (10.0)
≥3 2504/44 336 (5.6)
Smoking status
Nonsmoker or
past smoker
38 733/43 662 (88.7)
Current smoker 4929/43 662 (11.3)
Education leveld
Low 9677/31 574 (30.6)
Middle 10 647/31 574 (33.7)
High 11 250/31 574 (35.6)
Maternal Concentrations
Thyrotropin, mIU/Le 46 421 1.33 (0.13-4.52)
Free thyroxine, pmol/L 46 291 13.0 (7.2-21.9)
Thyroid peroxidase
antibody positivity
3043/40 559 (7.5)
Thyroglobulin
antibody positivity
1080/18 548 (5.8)
Pregnancy Characteristics
Gestational age
at birth, wk
47 045 39.9 (35.3-42.0)
Sex
Male 18 936/37 355 (50.7)
Female 18 419/37 355 (49.3)
Late preterm birth
(gestational age <37 wk)f
2357/47 045 (5.0)
Early preterm birth
(gestational age <32 wk)
349/47 045 (0.7)
SI conversion factor: To convert free thyroxine to ng/dL, divide by 12.871.
a The total No. indicates the No. of participants with available data on the
thyroid function tests. Cohort-specific descriptive characteristics appear in
eTable 1 in Supplement 2.
b Expressed as mean (SD).
c Calculated as weight in kilograms divided by height in meters squared.
dDefined as estimated years of education beyond primary school
(low: 0-4 years; middle: 4-8 years; high: >8 years).
e Often referred to as thyroid-stimulating hormone or TSH.
f Includes very preterm birth (<32 weeks’ gestational age).
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difference, −0.10% [95%CI, −0.20% to −0.01%] per 1 SD; OR,
0.88 per 1 SD [95% CI, 0.79 to 0.95]; Figure 3 and eTable 6 in
Supplement 2).
TPOAntibody and Thyroglobulin Antibody Positivity
Thyroid peroxidase antibody–positive women had a higher
risk of preterm birth vs TPO antibody–negative women
(6.6% vs 4.9%, respectively; absolute risk difference, 1.6%
[95% CI, 0.7% to 2.8%]; OR, 1.33 [95% CI, 1.15 to 1.56];
Figure 4) and very preterm birth (1.7% vs 0.7%; absolute risk
difference, 1.0% [95% CI, 0.6% to 1.7%]; OR, 2.45 [95% CI,
1.81 to 3.32]; Figure 4). There was no significant association
of thyroglobulin antibody positivity with preterm birth vs
those with thyroglobulin antibody negativity (4.3% vs 4.4%,
respectively; absolute risk difference, −0.5% [95% CI, −1.6%
to 0.9%]; OR, 0.88 [95% CI, 0.64 to 1.20]; eTable 6 in
Supplement 2).
Gestational Age at Birth
The results relating to the gestational age at birth were simi-
lar to those for preterm and very preterm birth (eTable 7 in
Supplement 2).
Sensitivity Analyses
In the prespecified sensitivity analysis, the results for thyro-
tropin concentration, FT4 concentration, and TPO antibody
positivity remained similar when all 3 exposures were added
to the same model, but the association of subclinical hypo-
thyroidismwith preterm birth was no longer statistically sig-
nificant after additional adjustment for TPOantibodypositiv-
ity (eTable 8 in Supplement 2).
In the post hoc sensitivity analysis on the association
of TPO antibody positivity with preterm and very preterm
birth, the P value for interaction for risk of preterm birth with
higher thyrotropin concentrations among TPO antibody–
positive women was .08; for very preterm birth, P < .001 for
interaction; and for gestational age at birth continuously,
P = .006 for interaction. Subsequent stratified analyses
showed that TPO antibody–positive women and a thyrotro-
pin concentration above 4.0 mIU/L had an excess risk of pre-
term birth vs TPO antibody–negative women (7.1% vs 4.9%,
respectively; absolute risk difference, 2.7% [95% CI, 0.2%-
6.3%]; OR, 1.55 [95% CI, 1.05-2.27]). However, stratified
analyses could not be performed for very preterm birth
(Figure 4).
In a post hoc sensitivity analysis, alternative TPO anti-
body concentration cutoffs were significantly associated with
a higher risk of preterm birth, but the results were similar to
those identified for manufacturer-based cutoffs (eTable 9 in
Supplement 2). In the prespecified analysis on the associa-
tion of thyroid function with preterm birth, TPO antibody
positivity or thyroglobulin antibody positivity did not differ
significantly according to the gestational age at the time of
blood sampling, BMI, or parity (P > .07 for interaction for all
analyses without meaningful differences after stratification;
eTables 10 and 11 in Supplement 2).
The primary analyses were similar using a 2-step ap-
proach;however, somecohort-specific analyseswithvery few
cases exhibited inflated ORs (eFigures 1 and 2 in Supple-
ment 2). The funnel plots did not indicate any bias and the
I2 values were mostly less than 40%. However, for the analy-
ses of TPO antibody–positive women, the I2 values were 77%
Figure 2. Association of Thyroid Function Test AbnormalitiesWith Preterm Birth
–3 –1–2 1 52 3 4
Risk Difference (95% CI), %
0
Favors
Lower
Risk
Favors
Higher
Risk
Favors
Lower
Risk
Favors
Higher
Risk
510.4
Odds Ratio (95% CI)
No. of Events/
Total No. (%)
Preterm birth (gestational age <37 wk)
Risk Difference
(95% CI), % P Value
Odds Ratio
(95% CI)
1859/37 202 (5.0)Euthyroid (reference group)
75/1234 (6.1)Subclinical hypothyroidism 1.4 (0 to 3.2) 1.29 (1.01 to 1.64) .03
35/594 (5.9)Subclinical hyperthyroidism 1.0 (–0.8 to 3.5) 1.20 (0.84 to 1.70) .29
13/328 (4.0)Overt hyperthyroidism –1.2 (–2.8 to 1.7) 0.76 (0.43 to 1.34) .35
64/904 (7.1)Isolated hypothyroxinemia 2.3 (0.6 to 4.5) 1.46 (1.12 to 1.90) .004
Very preterm birth (gestational age <32 wk)
289/37 202 (0.8)Euthyroid (reference group)
9/1234 (0.7)Subclinical hypothyroidism 0 (–0.3 to 0.8) 1.03 (0.52 to 2.01) .92
5/594 (0.8)Subclinical hyperthyroidism 0 (–0.4 to 1.2) 1.05 (0.43 to 2.58) .90
1/328 (0.3)aOvert hyperthyroidism
17/904 (1.9)Isolated hypothyroxinemia 1.2 (0.4 to 2.5) 2.57 (1.55 to 4.27) <.001
All analyses were adjusted for maternal age, bodymass index, ethnicity,
smoking, parity, gestational age at blood sampling, and fetal sex. Euthyroid was
defined as the 2.5th-97.5th cohort-specific percentile for thyrotropin (often
referred to as thyroid-stimulating hormone or TSH) and free thyroxine (FT4)
concentrations; subclinical hypothyroidism, increased thyrotropin
concentration with a normal FT4 concentration; subclinical hyperthyroidism,
decreased thyrotropin concentration with a normal FT4 concentration;
overt hyperthyroidism, decreased thyrotropin concentration with an increased
FT4 concentration; and isolated hypothyroxinemia, a normal thyrotropin
concentration with a decreased FT4 concentration. These clinical entities were
calculated for cohorts that had thyrotropin concentration, FT4 concentration,
and thyroid peroxidase antibody data available. Absolute differences and
corresponding 95% CIs were back-calculated from the results of multivariable
models and adjusted for baseline risk imprecision.
a There were too few samples to conduct a reliable analysis.
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for pretermbirth and69% for very pretermbirth (eFigure 2 in
Supplement 2).
Discussion
Subclinical hypothyroidism, isolatedhypothyroxinemia, and
TPO antibody positivity were associated with higher risk for
preterm birth. Isolated hypothyroxinemia and TPO antibody
positivity were associated with higher risk for very preterm
birth. The association of TPO antibody positivity with pre-
term birth did not appear to be related to differences in thy-
roid function, but was modified by the thyrotropin concen-
trationasexemplifiedby thehigher riskofpretermbirth inTPO
antibody–positive women and a thyrotropin concentration
above 4.0 mIU/L.
Because randomized trials of treatment of thyroid func-
tion test abnormalities during pregnancy are scarce, observa-
tional studies form the basis of clinical guidelines on thyroid
function and pregnancy.20 However, previous observational
studies on the association of thyroid function and autoimmu-
nity with preterm birth have used widely different defini-
tions for thyroid function test abnormalities. This variation
limits the ability to develop clearly defined recommenda-
tions in international guidelines and perform aggregate data
meta-analysis. Furthermore, most studies lacked statistical
power to study the risk of very preterm birth, a more clini-
cally relevant outcome related to high mortality and morbid-
ity, the demand for specialist neonatal services, and financial
burdens.22-24 By collecting individual participant data, the
current study allowed for standardization of the definition of
thyroid function test abnormalities.
To our knowledge, the current study is the first indi-
vidual participant data meta-analysis that shows isolated
hypothyroxinemia is associated with a higher risk of preterm
birth and very preterm birth and produced estimates in the
same range as well-known risk factors such as adolescent or
older maternal age, low BMI, obesity, smoking, and bacterial
vaginosis.12,13,25-27 These results are in line with those from a
previous population-based study, but opposite to those from
an aggregate data meta-analysis including 5 studies.15,28 Iso-
lated hypothyroxinemia is a pregnancy-specific disease
entity with a multifactorial underlying pathophysiology that
has remained relatively understudied.29
Figure 3. Association of Thyrotropin and Free Thyroxine (FT4) ConcentrationsWith Preterm Birth
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FT4 and very preterm birth
OR, 0.88 (95% CI, 0.79-0.98); P = .03
Preterm birth was defined as less than 37 weeks’ gestational age and very
preterm birth was defined as less than 32 weeks’ gestational age. The
thyrotropin and FT4 concentrations for all cohorts were log transformed and
then standardized to population-specific standard deviation scores after
removal of outliers (±4 SD from themean) to enable comparison between
different cohorts and assays. All analyses were adjusted for maternal age, body
mass index, ethnicity, smoking, parity, gestational age at blood sampling, and
fetal sex. OR indicates odds ratio.
Association of Thyroid Function Test Abnormalities and Thyroid AutoimmunityWith Preterm Birth Original Investigation Research
jama.com (Reprinted) JAMA August 20, 2019 Volume 322, Number 7 637
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Cardiff University User  on 09/30/2019
Available evidencepredominantly links isolatedhypothy-
roxinemia to suboptimal neurocognitive development of the
offspring,29,30 but international guidelines do not recom-
mend levothyroxine treatment inwomenwith isolatedhypo-
thyroxinemia because randomized clinical trials have not
proven a beneficial effect on child IQ.20 In 2 large randomized
clinical trials in which women with isolated hypothyrox-
inemia were treated with levothyroxine during the first half
of pregnancy, there was no statistically significant difference
in preterm birth with treatment. In 1 trial of pregnant women
with either subclinical hypothyroidism or isolated hypothy-
roxinemia, preterm birth occurred in 5.6% of the levothyrox-
inegroupvs7.9%of thecontrol group.31 In thesecondtrialwith
pregnant women who had isolated hypothyroxinemia, pre-
term birth occurred in 12% of the levothyroxine group vs 8%
of the placebo group and birth at less than 34 weeks’ gesta-
tional age occurred in 4% of the levothyroxine group and 3%
of the placebo group.32
Consistentwiththeresultsofthecurrentstudy,womenwith
isolated hypothyroxinemia in the 2 trials31,32 had higher pre-
termbirth rates thaneuthyroidwomendid in thecurrentmeta-
analysis. The results of the current study provide further in-
sightsonpotential risksof isolatedhypothyroxinemia thatmay
help tooptimizeclinicaldecision-makingstrategies, taking into
account all potential harms and benefits of screening pro-
gramsand subsequent levothyroxine treatment. Further stud-
ies will be required to elucidate the underlying pathophysiol-
ogyof isolatedhypothyroxinemiaand to study if it is also a risk
factor for other adverse pregnancy outcomes.
In the current study, TPO antibody positivity was associ-
ated with a higher risk of preterm birth, consistent with pre-
vious smaller meta-analyses using aggregate data and studies
onmiscarriage.12,13 Two recent clinical trials showed that pre-
conception treatment of euthyroid TPO antibody–positive
women who had either a previous miscarriage or fertility
treatment with low-dose levothyroxine neither reduced the
rate of preterm birth, nor any other pregnancy or neonatal
outcomes.33,34 These studiesdidnot includewomenwith thy-
roid function test abnormalities.33,34 The results of the cur-
rent studyshowahigher risk forTPOantibody–positivewomen
anda thyrotropin concentrationhigher than4.0mIU/L,which
confirms the results from a small randomized clinical trial
showing that levothyroxine treatment in TPO antibody–
positive women lowers preterm birth rates only if the thyro-
tropin concentration was higher than 4.0 mIU/L.35
Taken together, the results of this study are in alignment
with the recommendation of the American Thyroid Associa-
tion that different thyrotropin cutoffs should be used for TPO
antibody–positivewomenvsTPOantibody–negativewomen.20
A sensitivity analysis showed that the association of subclini-
cal hypothyroidism with preterm birth was no longer appar-
ent after additional adjustment for TPO antibody positivity,
suggesting that it is the TPOantibodypositivity that occurs in
one-thirdofwomenwith subclinical hypothyroidism that un-
derliesanyassociationsofsubclinicalhypothyroidismwithpre-
term birth. However, this study lacked statistical power for a
subgroup analysis on the associationof TPOantibodypositiv-
ity incombinationwithathyrotropinconcentrationhigher than
2.5mIU/L for preterm birth or higher than 4.0mIU/L for very
preterm birth.
There remains an important role for observational stud-
ies in theevaluationof thyroid function test abnormalitiesdur-
ing pregnancy. For example, observational studies have indi-
cated that the interpretationof the results of large randomized
Figure 4. Association of Thyroid Peroxidase (TPO) Antibody PositivityWith Preterm Birth
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No. of Events/
Total No. (%)
Preterm birth (gestational age <37 wk)
Risk Difference
(95% CI), % P Value
Odds Ratio
(95% CI)
1847/37 516 (4.9)TPO antibody negative (reference group)
202/3043 (6.6)TPO antibody positive 1.6 (0.7-2.8) 1.33 (1.15-1.56) <.001
TPO antibody positive and
174/2566 (6.8) 1.8 (0.7-2.9) 1.36 (1.15-1.60) <.001Thyrotropin within normal range
64/989 (6.5)Thyrotropin >2.5 mIU/L 1.8 (0.2-3.7) 1.36 (1.05-1.76) .01
29/406 (7.1)Thyrotropin >4 mIU/L 2.7 (0.2-6.3) 1.55 (1.05-2.27) .02
Very preterm birth (gestational age <32 wk)
268/37 516 (0.7)TPO antibody negative (reference group)
53/3043 (1.7)TPO antibody positive 1.0 (0.6-1.7) 2.45 (1.81-3.32) <.001
TPO antibody positive anda
52/2566 (2.0) 1.3 (0.8-2.0) 2.86 (2.10-3.89) <.001Thyrotropin within normal range
7/989 (0.7)bThyrotropin >2.5 mIU/L
0/406 (0)bThyrotropin >4 mIU/L
All analyses were adjusted for maternal age, bodymass index, ethnicity,
smoking, parity, gestational age at blood sampling, and fetal sex. Absolute
differences and corresponding 95% CIs were back-calculated from the results
of multivariable models and adjusted for baseline risk imprecision.
a Thyroid peroxidase antibody–positive women and thyrotropin (often referred
to as thyroid-stimulating hormone) concentrations within the normal range or
higher than 2.5 mIU/L and 4mIU/L were compared with TPO
antibody–negative women regardless of their thyrotropin concentration.
b There were too few samples to conduct a reliable analysis.
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trials31-34 may be limited because of risks related to potential
overtreatment, a late start of levothyroxine therapy, or sole in-
clusion ofwomenwith normal thyroid.36-39Moreover, obser-
vational studies are needed to study detrimental clinical out-
comes with a relatively low incidence such as very preterm
birth,giventhe impracticalityof randomizedtrials for suchout-
comes. For example, to study if levothyroxine therapy could
reverse excess preterm birth risks as identified in this study
for isolated hypothyroxinemia, TPO antibody positivity, and
TPO antibody positivity with a thyrotropin concentration
greater than4.0mIU/L, a totalof3674,6090,and3814women,
respectively,would have to be randomized,which in the case
of population screening would translate to the screening of
196470, 95 530, and 448706 women (with a 2-sided α level
of .05, a power level of 80%, and a lost to follow-up rate or de-
clined participation rate of 15%).
The results of the current study do not change the con-
siderationthat there iscurrently insufficientevidenceforaben-
efit of routine thyroid function screening in pregnant wom-
en; thepotential harmsandbenefits of levothyroxine forother
clinicallymeaningful outcomes should be taken into account
as well. The results support the concept of a reflex TPO anti-
body measurement in women with a thyrotropin concentra-
tionhigher than4.0mIU/L, andgestational thyrotropinmoni-
toring for TPO antibody–positivewomen prior to conception.
The current study in itself does not validate a reflex FT4 con-
centration or TPO antibody measurement for women with a
normal thyrotropin concentration until further randomized
trials are performed.
The results of the current study add to the limited knowl-
edge on the complicated and multifactorial mechanisms un-
derlying preterm and very preterm birth.40 Because thyroid
hormone regulates keyprocesses inplacental and fetal growth
anddevelopment, theassociations forFT4concentrationcould
be mediated via effects on either placental function, fetal
growth, or both.8,9,11,40,41 Alternatively, thyroid hormone and
TPOantibodypositivity couldbe involved in infectious and in-
flammatory pathways leading to preterm birth.42,43 Another
potential mechanism by which low thyroid hormone avail-
ability couldbeassociatedwithpretermbirth is that itmay lead
to an earlier onset of labor via an increase in oxytocin and va-
sopressin, but a decrease in progesterone, or through thyroid
hormone effects specific for the cervix, endometrium, or fe-
tal membranes.7,44-47 Further studies on pathways via which
thyroid hormone is involved in the pathogenesis of preterm
birth are needed to further optimize risk identification.
Limitations
This studyhas several limitations.First, therewasa lackof sta-
tistical power to optimally investigate the risk of very pre-
term birth in specific clinically relevant subgroups. Although
very preterm birth is clinically more relevant than late pre-
term birth, the relatively sparse occurrence of TPO antibody
positivity combined with a thyrotropin concentration higher
than2.5 or 4.0mIU/Lnecessitates an even larger data set than
thatavailable in thecurrent study toexamineassociationswith
very preterm birth.
Second, only 5 of the 19 studies haddata available on thy-
roglobulin antibodies. Although this association was studied
ina largenumberofwomen,datawereonlyavailable for40.0%
of included women, which may have affected the results.
Third, pregnancy-related changes in thyroid-bindingpro-
teinscould interferewithFT4 immunoassays.However, theuse
of assay-specific reference ranges as advocated by the cur-
rent American Thyroid Association guidelines and standard-
izationofFT4concentrationsper cohortorassayshouldmostly
eliminate the potential between-assay differences in abso-
lute FT4 concentrations.
Fourth, studies thatwerepublishedwhile conducting sta-
tistical analyses for the current study could not be included.
Fifth, because the included studies were observational, re-
sidual or unmeasured confounding cannot be excluded.How-
ever, theanalysis of individual participantdata allowed for ad-
justment for multiple relevant confounders. Sixth, causality
cannot be determined from observational studies.
Conclusions
Among pregnant women without overt thyroid disease, sub-
clinical hypothyroidism, isolatedhypothyroxinemia, andTPO
antibody positivity were significantly associated with higher
riskofpretermbirth.These resultsprovide insights towardop-
timizing clinical decision-making strategies that should con-
sider the potential harms and benefits of screening programs
and levothyroxine treatment during pregnancy.
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